



Division of Medical Services Pharmacy Program

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851



ARKANSAS MEDICAID DUR BOARD QUARTERLY DRUG UPDATE APRIL 15, 2026 8:30 A.M. – 12:30 P.M. VIRTUAL TEAMS MEETING LINK

Microsoft Teams [Need help?](#)

[Join the meeting now](#)

Meeting ID: 259 819 253 129 14

Passcode: qj6Gf2Gd

Dial in by phone

[+1 501-244-3310,578620884#](tel:+15012443310578620884) United States, Little Rock

[Find a local number](#)

Phone conference ID: 578 620 884#

****TENTATIVE AGENDA IS SUBJECT TO CHANGE****

I. OUTSIDE SPEAKERS

Per the DUR Board Bylaws Section 7.02 Outside Speakers -- Outside speakers with clinical or scientific credentials or patient experience pertinent to a product or topic that is posted on the upcoming DUR Board meeting agenda may request to speak on that product or topic. Public comments will not be permitted for topics not included on the agenda. Requests to speak at the DUR Board meeting must be made in writing to the DUR Chairperson at least two (2) weeks before the DUR Board meeting date, and should include:

- (1) The speaker's name, title, relevant credentials, and organization;
- (2) Contact information for the speaker including address, telephone number, and email;
- (3) The agenda item(s) which the speaker intends to address;
- (4) Prepared comments which are not a reiteration of the FDA approved package insert; and
- (5) Any educational materials for Board members in advance of the meeting.

This information shall be included in information sent to Board members two (2) weeks prior to the Board meeting. Presentations or public comments given at the DUR Board meeting are limited to a total of **three (3) minutes** per drug, which may be shared by multiple speakers. This time limit does not include responses to any questions raised by DUR Board members during the course of the meeting.

A copy of the proposed criteria for the specific agenda item on which an individual requests to speak may be requested from the Chairperson three (3) weeks prior to the DUR Board meeting. The information will be in draft form and may be changed by the DUR Board prior to being finalized. As such, the draft criteria should not be shared with clinicians or patients.

II. UNFINISHED / OLD BUSINESS AND GENERAL INFORMATION

A. ANNOUNCEMENTS

B. APPROVAL OF THE MINUTES FROM THE PREVIOUS MEETING.

C. UPDATE ON SYSTEM EDITS, IMPLEMENTATIONS, OR FOLLOW-UP ITEMS.

- 1) Follow-up items from January 21, 2026 DUR Board
- 2) Implementation information from January 21, 2026 DUR Board

D. GENERAL INFORMATION

- 1) **New medications following the oncology policy**
- 2) **PAD Subcommittee Report**
- 3) **Wegovy (semaglutide) tablets—informational only and no vote required**

<https://humanservices.arkansas.gov/>

Protecting the vulnerable, fostering independence and promoting better health



III. PDL CLASS REVIEW AND CRITERIA/EDIT CHANGES

A. PDL CLASS REVIEW WITHOUT CRITERIA

- 1) H2 RECEPTOR BLOCKERS (New Class)

B. PDL CLASS REVIEW WITH CRITERIA (see specific medications on page 3)

- 1) THYROID PRODUCTS (New Class)
- 2) OCTREOTIDE and RELATED AGENTS (New Class)
- 3) DIURETICS (New Class)
 - a) ENBUMYST—new PA criteria
 - b) LASIX ONYU—new PA criteria
- 4) OSTEOPOROSIS, BONE RESORPTION AND SUPPRESSION AGENTS

C. ESTABLISHED PDL CLASS REVIEW WITHOUT ANTICIPATED CHANGE

- 1) ANTIDEPRESSANTS
- 2) PITUITARY SUPPRESSIVE AGENTS
- 3) CII STIMULANTS
- 4) LIPOTROPICS EXCLUDING STATINS

IV. NEW BUSINESS

A. PROPOSED NEW CLINICAL POINT OF SALE CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS: None

B. PROPOSED MANUAL REVIEW CRITERIA FOR CERTAIN DISEASE STATES:

- 1) OSTEOPOROSIS
- 2) ALLERGIC FUNGAL RHINOSINUSITIS

C. PROPOSED CHANGES TO EXISTING CRITERIA and EDITS, INCLUDING POINT OF SALE (POS) CRITERIA, MANUAL REVIEW PA CRITERIA, OR CLAIM EDITS:

- 1) LEQVIO (inclisiran) injection

D. PROPOSED NEW MANUAL REVIEW CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:

- 1) CARDAMYST (etripamil) spray
- 2) REDEMPLO (plozasiran) injection
- 3) VOYXACT (sibeprenlimab) injection
- 4) AQVESME (mitapivat) tablet
- 5) MYQORZO (aficamten) tablet
- 6) FORZINITY (elamipretide hydrochloride) injection
- 7) ZYCUBO (copper histidinate) injection
- 8) PIVYA (pivmecillinam) tablet
- 9) LOARGYS (pegzilarginase-nbln) vial
- 10) YUVEZZI (carbachol-brimonidine) drops

E. PROPOSED NEW CLAIM EDITS (QUANTITY, DAILY DOSE, ACCUMULATION, GENDER, AGE):

F. ProDUR REPORT UPDATE

G. RDUR REPORT UPDATE



PDL THERAPEUTIC CLASSES UNDER REVIEW
H2 RECEPTOR BLOCKERS (New Class): cimetidine tablet, cimetidine solution, OTC dual action complete chew, OTC acid reducer, famotidine tablet, famotidine suspension, nizatidine capsule, ranitidine tablet
THYROID PRODUCTS (New Class): Adthyza tablet, Armour thyroid tablet, Ermeza solution Evexithroid tablet, levothyroxine tablets, Niva thyroid tablet, NP thyroid tablet, Renthroid tablet, Synthoid tablets, Thyquidity solution
OCTREOTIDE and RELATED AGENTS (New Class): Bynfezia injection, lanreotide acetate injection, Mycapssa capsule, octreotide ER injection, octreotide vial/syringe/ampule, Palsonify tablet, Sandostatin LAR Depot, Sandostatin ampule, Signifor LAR, Signifor ampule, Somavert injection, Somatulilne Depot injection
DIURETICS (New Class): Aldactone tablet, amiloride tablet, amiloride/HCTZ tablet, bumetanide tablet, Carospir suspension, chlorthalidone tablet, Enbumyst spray, eplerenone tablet, ethacrynic acid tablet, furosemide solution, furosemide tablet, Hemiclor tablet, HCTZ capsule, HCTZ tablet, indapamide tablet, Inspra tablet, Inzirqo suspension, Kerendia tablet, Lasix tablet, Lasix Onyu kit, metolazone tablet, spironolactone tablet, spironolactone suspension, spironolactone/HCTZ tablet, Thalitone tablet, torsemide tablet, triamterene capsule, triamterene/HCTZ capsule, triamterene/HCTZ tablet
OSTEOPOROSIS, BONE RESORPTION AND SUPPRESSION AGENTS: Actonel tablet, alendronate solution, alendronate tablet, Atelvia DR tablet, Aukelso vial , Bildyos syringe , Bilprevda vial , Binosto eff tablet, Bomynta syringe/vial , Bonsity pen, Bosaya syringe , calcitonin-salmon spray, Conexence syringe , Enoby syringe , Evenity syringe, Evista tablet, Forteo pen, Fosamax tablet, Fosamax Plus D tablet, ibandronate tablet, Jubbonti syringe , Osenvelt vial , Prolia syringe, raloxifene tablet, risedronate tablet, Stoboclo syringe , teriparatide pen, Tymlos pen, Wyost vial , Xgeva vial, Xtrenbo vial

**Bolded are new to the market since last review or were not listed on the PDL document, and stricken meds are no longer on the market or will be unavailable soon.